Aurobindo Pharma subsidiary CuraTeQ Biologics has received Notice of Compliance (NOC) from Health Canada’s Biologics and Radiopharmaceutical Drugs Directorate (BRDD) for Bevqolva, its bevacizumab biosimilar.
A humanised monoclonal antibody, Bevacizumab slows tumor vascular growth and treats multiple cancers, including colorectal and lung. The originator product Avastin is marketed by Roche/Genentech.